Form 4: ARDX CHRO Granted 99,455 RSUs, 149,185 Stock Options

ARDELYX, Inc.'s Chief Human Resources Officer, James Parker Brady, was granted 99,455 restricted stock units and 149,185 stock options.

Summary

• James Parker Brady, Chief Human Resources Officer of ARDELYX, INC. (ARDX), acquired 99,455 shares of Common Stock in the form of Restricted Stock Units (RSUs) on January 23, 2026.
• Each RSU entitles the Reporting Person to receive one share of Common Stock upon vesting.
• Brady also acquired 149,185 stock options with an exercise price of $7.77 per share on January 23, 2026.
• These stock options have an expiration date of January 23, 2036.
• The options vest in 48 successive, equal monthly installments on each monthly anniversary of January 23, 2026, contingent on continued employment or service with ARDELYX, INC.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation grant, which is a neutral to slightly positive event as it aligns management incentives with shareholder interests and aids in executive retention. It does not introduce new material financial or operational information.

Positives

• The grant of 99,455 Restricted Stock Units (RSUs) and 149,185 stock options aligns the Chief Human Resources Officer's interests with those of shareholders, promoting long-term value creation.
• Equity grants are a standard mechanism for executive retention, incentivizing continued service and performance.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule of the granted equity awards, which is contingent on continued employment.

Industry Context

The grant of restricted stock units and stock options to a Chief Human Resources Officer is a common practice in the biotechnology and pharmaceutical industry for executive compensation, aiming to attract, retain, and motivate key personnel by linking their compensation to the company's long-term performance.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with multi-year vesting schedules, is consistent with typical executive compensation packages observed across the biotechnology and broader public company landscape.
• While specific comparable companies or projects are not detailed in the filing, this type of grant is a standard tool used by companies like Amgen, Gilead Sciences, and Biogen to incentivize and retain executives.

Related Party Transactions

• The grant of equity awards to James Parker Brady, an officer of ARDELYX, INC., constitutes a related party transaction as it involves compensation provided by the company to a key executive.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting and exercise of options, but also benefits from enhanced alignment of executive incentives with long-term company performance.
• Employees: Reflects standard executive compensation practices within the company, potentially influencing overall compensation philosophy.

Next Steps

• The Reporting Person's continued employment or service relationship with ARDELYX, INC. is required for the vesting of the granted RSUs and stock options.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation grant of restricted stock units and stock options. It does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The grants are standard practice for executive retention and aligning management interests with long-term shareholder value, thus maintaining a 'hold' stance is appropriate.

Keywords

ARDELYX, ARDX, Form 4, James Parker Brady, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Equity Grant